Evaxion Biotech Announces New CEO and Promising Vaccine Developments

Evaxion Biotech ( (EVAX) ) has issued an update.

On November 6, 2025, Evaxion A/S announced significant business developments and financial results for the third quarter of 2025. Key highlights include the appointment of Dr. Helen Tayton-Martin as the new CEO, effective November 24, 2025, and the presentation of promising phase 2 trial data for their personalized cancer vaccine, EVX-01, at the ESMO Congress. The company also reported the out-licensing of their bacterial vaccine candidate, EVX-B3, to MSD, which has extended their cash runway to the second half of 2027. These developments underscore Evaxion’s strategic focus on leveraging its AI-Immunology™ platform for vaccine innovation and expanding its market presence through strategic partnerships.

The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.

Spark’s Take on EVAX Stock

According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.

Evaxion Biotech’s overall score is driven by strong technical indicators and positive developments from the earnings call, including R&D progress and financial stability. However, financial performance remains a concern due to ongoing losses and reliance on debt, impacting the valuation negatively.

To see Spark’s full report on EVAX stock, click here.

More about Evaxion Biotech

Evaxion A/S is a clinical-stage TechBio company based in Denmark, specializing in the development of AI-Immunology™ powered vaccines. The company focuses on creating innovative vaccines for cancer and infectious diseases, leveraging artificial intelligence to enhance vaccine design and target discovery.

Average Trading Volume: 1,591,013

Technical Sentiment Signal: Sell

Current Market Cap: $35.37M

Learn more about EVAX stock on TipRanks’ Stock Analysis page.